Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
about
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysisChallenging and complex decisions in the management of the BRCA mutation carrierTamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomyImproving symptom communication through personal digital assistants: the CHAT (Communicating Health Assisted by Technology) project.Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body StudyOngoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.Current strategies for the prevention of breast cancerEndometrial profile of tamoxifen and low-dose estradiol combination therapy.How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition.p53-Independent apoptosis by benzyl isothiocyanate in human breast cancer cells is mediated by suppression of XIAP expressionWithaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species.Amelioration of sexual adverse effects in the early breast cancer patientWithaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells.Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update.Hot flashes in breast cancer survivors and an association with calcium supplement use.Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogenArzoxifene: the evidence for its development in the management of breast cancer.Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007.Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivorsTreatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors.Withaferin a suppresses estrogen receptor-α expression in human breast cancer cellsBenzyl isothiocyanate inhibits epithelial-mesenchymal transition in cultured and xenografted human breast cancer cellsCombinational treatment of gap junctional activator and tamoxifen in breast cancer cells.Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.Relationship between exercise behavior, cardiorespiratory fitness, and cognitive function in early breast cancer patients treated with doxorubicin-containing chemotherapy: a pilot study.Single-nucleotide polymorphism in microRNA-binding site of SULF1 target gene as a protective factor against the susceptibility to breast cancer: a case-control study.Recommendations for raloxifene use in daily clinical practice in the Swiss setting.Hereditary diffuse gastric cancer: association with lobular breast cancer.Raloxifene and the prevention of breast cancer.Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trialLiving my family's story: identifying the lived experience in healthy women at risk for hereditary breast cancer.Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors.Affective forecasting and medication decision making in breast-cancer preventionQuality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancerThe half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.Symptom burden: multiple symptoms and their impact as patient-reported outcomes.Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention
P2860
Q26773464-EE71C2E9-4FAD-43A1-AB25-262719723760Q27026559-E7767EC3-F0F7-4151-A2B9-6DE6DC9EBF1CQ28300092-243902CE-F825-44D6-9324-C2E608C27992Q30562213-7046A1AF-3DE3-48F1-B99B-63F6DBC7162EQ30758966-487265ED-DBF1-473A-8F50-FDE29EE2D1ADQ31001228-EA6F3A81-52AE-4ABC-88EC-901CB8C61EF9Q33599463-CA3CBFF9-E3E8-4A52-B1F4-783D7B3B8496Q33638802-DA2B5AE4-87CA-43B0-B67D-9337B8DD1958Q33767120-0E928078-EDD9-496A-B93C-35D3DE5E29ECQ33841626-EF939424-B3B3-4900-95A5-6D1243CB1024Q33895595-41C959FC-BC8A-41F8-9C14-82E405694C1CQ33997100-343C668A-DD9E-4C0E-AA24-46FB98248BEDQ34065198-B409C334-79BA-4022-8755-5B12A8EFBA7DQ34253370-6FE59E2F-4D7E-43C3-8F16-B0800B3E467AQ34272056-85656674-6262-47FC-BB33-14770004416DQ34345637-3AEFCB5E-BFC4-4ECF-8241-6672D5C306B5Q34446978-4F063951-3F92-4DCE-BA4A-3E738C035674Q34449901-6C932276-F1ED-4DD9-9A16-099613380F87Q34818002-E86F591E-E9E2-4F0A-BBF7-4B197916855FQ34877439-4F468BEC-F558-416E-801E-B218364750D4Q34878309-177F6F7D-016D-47B9-8757-4D9B970B6510Q34896573-1A73E942-9820-4B04-A586-95EBB108869FQ35038872-F4BB666E-CD04-4BB4-87D6-442EA98D56A3Q35085709-FA91800B-0C4C-4A32-9FD1-8A3DF7F73841Q35091219-4505383E-11EF-424E-B38F-160A28FA67E3Q35230023-7AC22370-1353-4807-9703-9A701E568938Q35845258-327130E6-50E5-4532-B545-C0515BB2EAA2Q35972547-E53379D4-97C3-4321-BB53-AA86FE488FC2Q36044425-4B84AB36-ADBB-46BE-948B-C76EB3897038Q36428565-74A9B3EA-A6B3-4ECA-BEFB-4C4D305AEF81Q36477282-331E8163-71E4-477E-9392-C1013D3F197BQ36632266-4F20AAC3-5CD5-42D6-B249-FA5E65DAA361Q36689309-E88E87E3-0A3B-4D07-9F75-2E36B795825EQ36792824-2B97358A-5522-40DB-BC3E-F9EB4A8DC266Q36815909-8BD3D031-068A-470D-AC45-54985433D2BCQ36905513-E78C1F1A-EC06-42BC-B770-B7C1EF13E6E7Q36934323-A8D0A57A-8EB5-4955-876A-B4228FA3D028Q36973199-A00A5E43-B1A7-43A4-824D-98289CE80265Q36977007-3B4FA1F3-773E-4F78-BCCB-44F78FFD5351Q37097084-5F2FC797-C7CA-4CDF-A564-3F5EC895AFED
P2860
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Patient-reported symptoms and ...... d Raloxifene (STAR) P-2 trial.
@en
type
label
Patient-reported symptoms and ...... d Raloxifene (STAR) P-2 trial.
@en
prefLabel
Patient-reported symptoms and ...... d Raloxifene (STAR) P-2 trial.
@en
P2093
P1476
Patient-reported symptoms and ...... d Raloxifene (STAR) P-2 trial.
@en
P2093
D Lawrence Wickerham
Eduardo R Pajon
James B Lockhart
James L Wade
Joseph P Costantino
Marcie W Ritter
Myoungkeun Lee
Norman Wolmark
Patricia A Ganz
Shaker Dakhil
P304
P356
10.1001/JAMA.295.23.JOC60075
P407
P577
2006-06-05T00:00:00Z